Investigating how RNA-binding proteins can reduce toxicity caused by FUS in yeast.
Official title: Mechanisms of RNA binding proteins rescuing FUS induced toxicity in yeast
Funded at Wright State University · NIH-10202952 · Data updated 2026-11-12
This study is looking at how certain proteins in our cells can help protect against the harmful effects of a protein linked to ALS, and it aims to find new ways to treat people with this condition.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2021 |
| Award (this year) | $450,000 |
| NIH project number | 1R15NS109804-01A1 |
| Project ID | NIH-10202952 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Amyotrophic Lateral Sclerosis or those at risk of developing the disease.
✕Less likely to help
Patients with other neurological disorders unrelated to ALS may not benefit from this research.
What this research studies
This research focuses on understanding the role of RNA-binding proteins (RBPs) in mitigating the toxic effects of FUS, a protein linked to Amyotrophic Lateral Sclerosis (ALS). Using a yeast model, researchers have identified several human genes that can counteract FUS toxicity. The study aims to explore the mechanisms by which these RBPs function and their potential as therapeutic targets for ALS. By leveraging advanced genetic screening techniques, the research seeks to uncover new pathways that could lead to effective treatments for patients suffering from ALS.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating ALS, potentially improving the quality of life for patients.
How similar studies have gone: Previous research has shown promise in using similar approaches to identify therapeutic targets for ALS, indicating a potential for success in this study.
Where this research is happening
-
Wright State University
Dayton, United States Active
Researchers
- Principal investigator: Ju, Shulin — Wright State University
- Study coordinator: Ju, Shulin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.